Clinical trials & evidence

ADA 2026 findings show diabetes drugs are no longer just chasing glucose

Oral SERDs Face the Hard Test: Where Do They Actually Fit?

Prostate Cancer Value Starts Counting Cognition

China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone

The ASCO Drug Race Still Runs Through Genomic Testing

High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Alzheimer’s Blood Testing Moves the Disease Clock Earlier

Physical activity continues to strengthen its case as a cross-disease prevention strategy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
